6 he central function of an animal’s immune system is to adaptively respond to a foreign target such as an invading pathogen through a process of diversification and selection that produces novel antibodies with high affinity, specificity, and expression. The human body has approximately a billion different antibodies circulating in the bloodstream, and an iterative process preferentially selects those that are naturally optimized to neutralize an antigen. Drug developers have attempted to imitate this highly sophisticated biological process to produce therapeutic antibodies against pathogens and human targets using synthetic methods, yet, as of the end of 2022, 90% of regulatory-approved antibodies for human use have been derived from natural sources. This strong track record, industry momentum, and significant government investment has driven continued interest in antibody discovery, development, and methods that are continually sought to make the process more efficient. Historically, most approved therapeutic antibodies have been sourced from the immunization of animals necessitating subsequent ex-vivo engineering to humanize them to reduce their risk of immunogenicity and toxicity in humans. These additional OmniAb’s mission is to enable the rapid development of innovative antibody therapeutics by providing its leading pharmaceutical and biotechnology partners with cutting-edge antibody discovery technologies. By combining the expansive and diverse antibody repertoires generated from OmniAb’s groundbreaking four-species, in vivo discovery platform, with its cutting-edge, high-throughput screening tools and in silico capabilities, the company is delivering on its commitment of helping the industry discover the next-generation of therapeutic antibodies. Best Therapeutic Antibody Discovery Company 2023 - USA downstream steps can increase cost, time, and technical risks associated with a discovery or development program. Sourcing therapeutic antibodies from transgenic animals that have been engineered to produce human antibody sequences is an elegant solution to this problem because it harnesses the biological processes of animal immune systems to generate naturally optimized antibodies while simultaneously producing them in a human form, requiring minimal to no ex-vivo engineering. “The historical success rates for antibodies have been better than small molecules and the industry as a whole is also getting better at developing antibody-based medicines,” comments Matt Foehr, CEO of OmniAb, Inc. “Our technological platform, with its efficient nature and wide-ranging results, aims to overcome the industry challenges that remain. It provides partners with antibody candidates based on unparalleled biological diversity, which we believe, over time, shorten discovery timelines, reduce costs, and considerably improve the chances of success.” Leveraging Biological IntelligenceTM for Diverse Antibody Discovery Solutions With a team of world-renowned scientists at the helm, OmniAb has created an industry-leading portfolio of unique, transgenic animal hosts that provide diverse repertoires of humanized antibody candidates. This is all possible through the harnessing of Biological Intelligence, which refers to the ability of genetically engineered animals to generate optimized antibodies that can be developed into therapeutics. When paired with the company’s advanced screening technologies, it allows biopharmaceutical partners to discover highly promising antibody therapeutic candidates. Through natural optimization and minimal ex-vivo engineering, the antibodies generated have desirable affinity, specificity, developability, and functional performance. At the core of OmniAb’s Biological Intelligence are OmniRat®, OmniMouse®, and OmniChicken®, all of which have been genetically modified to generate human antibodies, designed to accelerate the development of human therapeutic candidates. OmniRat® was launched in 2012 and produces a diverse repertoire of antibodies containing human idiotypes and immunological characteristics comparable to antibodies found in wild-type animals. As of the end of September 2023, three approved antibodies are OmniRat derived, and an additional 23 are in clinical development through partner organizations. OmniMouse followed in 2014 and was designed using the same transgenes as its predecessor to deliver fully human antibodies. For partners preferring to work with mice, this platform offers a T Jul23706 Matt Foehr, CEO
RkJQdWJsaXNoZXIy MTUyMDQwMA==